Zidovudine and lamivudine: Drug information

For additional information see "Zidovudine and lamivudine: Patient drug information" and "Zidovudine and lamivudine: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table

ALERT: US Boxed Warning

Hematologic toxicity:

Zidovudine, a component of lamivudine/zidovudine tablets, has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.

Myopathy:

Prolonged use of zidovudine has been associated with symptomatic myopathy.

Exacerbations of hepatitis B:

Severe, acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, a component of lamivudine/zidovudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue lamivudine/zidovudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of antihepatitis B therapy may be warranted.

Lactic acidosis and severe hepatomegaly with steatosis:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with use of nucleoside analogues, including lamivudine and zidovudine. Discontinue lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.

Brand Names: US

Combivir [DSC]

Brand Names: Canada

APO-Lamivudine-Zidovudine;
Auro-Lamivudine/Zidovudine;
Combivir [DSC];
JAMP-Lamivudine/Zidovudine;
TEVA-Lamivudine/Zidovudine [DSC]

Pharmacologic Category

Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)

Dosing: Adult

Note: Because this is a fixed-dose combination product, avoid use in patients requiring dosage reduction.

HIV-1 infection, treatment

HIV-1 infection, treatment: Oral: One tablet (lamivudine 150 mg/zidovudine 300 mg) twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

CrCl ≥50 mL/minute: No dosage adjustment necessary.

CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components).

Dosing: Liver Impairment: Adult

Use is not recommended (use dose-adjusted individual components).

Dosing: Pediatric

(For additional information see "Zidovudine and lamivudine: Pediatric drug information")

HIV-1 infection, treatment

HIV-1 infection, treatment: Note: Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and https://hivdb.stanford.edu/ for more information).

Children and Adolescents weighing ≥30 kg: Lamivudine 150 mg and zidovudine 300 mg per tablet: Oral: One tablet twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents weighing ≥30 kg:

CrCl ≥50 mL/minute: No dosage adjustment necessary.

CrCl <50 mL/minute: Use of fixed-dose combination is not recommended; see individual agents.

Dosing: Liver Impairment: Pediatric

Children and Adolescents weighing ≥30 kg: Use of fixed-dose combination is not recommended; see individual agents.

Adverse Reactions

See individual agents.

Contraindications

Hypersensitivity to lamivudine or zidovudine, or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Neutrophil count <750/mm³ or hemoglobin <7.5 g/dL (4.65 mmol/L)

Warnings/Precautions

Concerns related to adverse effects:

• Hematologic toxicity: [US Boxed Warning]: Zidovudine is associated with hematologic toxicity, including neutropenia and severe anemia. Use with caution in patients with bone marrow compromise (granulocytes <1,000 cells/mm³ or hemoglobin <9.5 g/dL).

• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.

• Lactic acidosis/hepatomegaly: [US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Female gender and obesity may increase the risk for development. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).

• Lipoatrophy: Zidovudine may cause loss of subcutaneous fat, especially in the face, limbs, and buttocks. Lipoatrophy incidence and severity are related to cumulative exposure and may be only partially reversible; improvement may take months to years after switching to a regimen that does not contain zidovudine. Monitor patients for signs of lipoatrophy and consider switching to a non-zidovudine-containing regimen if lipoatrophy occurs.

• Myopathy: [US Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy.

Disease-related concerns:

• Chronic hepatitis B: [US Boxed Warning]: Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 when therapy is discontinued; monitor patients with clinical and laboratory follow-up for at least several months after treatment discontinuation. Emergence of hepatitis B virus lamivudine-resistant variants has been reported in patients with concurrent HBV infection who received a lamivudine-containing regimen for HIV-1 treatment.

• Hepatic impairment: Use is not recommended in patients with hepatic impairment.

• Pancreatitis: Use with caution in patients with a history of pancreatitis or other significant risk factors for pancreatitis development. Discontinue immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur.

• Renal impairment: Use is not recommended in patients with renal impairment (CrCl <50 mL/minute).

Warnings: Additional Pediatric Considerations

The major clinical toxicity of lamivudine in pediatric patients is pancreatitis, which occurred in 14% of patients in one open-label, dose-escalation trial; discontinue lamivudine therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. Use with extreme caution and only if there is no satisfactory alternative therapy in pediatric patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis (Epivir prescribing information 2020).

Zidovudine-related adverse hematologic effects may be concentration-dependent and associated with increasing AUC (Fillekes 2014; HHS [pediatric] 2023). Adverse cardiac effects have been associated with zidovudine therapy. A prospective study of 325 pediatric patients aged 7 to 16 years with perinatally acquired HIV evaluated associations between previous or current antiretroviral agents and cardiac echocardiogram measures. When comparing patients currently receiving zidovudine (n=107) with those who were not, zidovudine therapy was associated with increased end-systolic wall stress and slightly larger heart size. Longer duration of zidovudine use was associated with higher wall stress (Williams 2018). A descriptive study evaluated 643 individuals 1 to 25 years of age with perinatally acquired HIV to determine prevalence of early cardiac dysfunction and reported that left ventricular ejection fraction was negatively associated with history of zidovudine exposure. Implications for cardiac outcomes later in life (eg, cardiomyopathy) are unknown (McCrary 2020; Williams 2018).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Combivir: Lamivudine 150 mg and zidovudine 300 mg [DSC] [scored]

Generic: Lamivudine 150 mg and zidovudine 300 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (lamiVUDine-Zidovudine Oral)

150-300 mg (per each): $4.42 - $15.53

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Combivir: Lamivudine 150 mg and zidovudine 300 mg [DSC] [contains polysorbate 80]

Generic: Lamivudine 150 mg and zidovudine 300 mg

Administration: Adult

Oral: Administer without regard to food.

Administration: Pediatric

Oral: May be administered without regard to meals

Hazardous Drugs Handling Considerations

Zidovudine is a hazardous agent (NIOSH 2024 [table 2]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

HIV-1 infection, treatment: Treatment of HIV-1 infection in combination with other antiretrovirals.

Medication Safety Issues

Sound-alike/look-alike issues:

Combivir may be confused with Combivent, Epivir

Other safety concerns:

AZT is an error-prone abbreviation (mistaken as azaTHIOprine, aztreonam)

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Acemetacin: May increase adverse/toxic effects of Zidovudine. Specifically, the risk for hematologic toxicity may be increased. Risk C: Monitor

Amodiaquine: Zidovudine may increase neutropenic effects of Amodiaquine. Management: Avoid coadministration of zidovudine-containing antiretroviral therapy with amodiaquine when possible. If combined, monitor closely for neutropenia. Risk D: Consider Therapy Modification

Antithyroid Agents: Myelosuppressive Agents may increase neutropenic effects of Antithyroid Agents. Risk C: Monitor

Arimoclomol: May increase serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Atidarsagene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Atidarsagene Autotemcel. Risk X: Avoid

BCG (Intravesical): Myelosuppressive Agents may decrease therapeutic effects of BCG (Intravesical). Myelosuppressive Agents may increase adverse/toxic effects of BCG (Intravesical). Risk X: Avoid

Betibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Betibeglogene Autotemcel. Risk X: Avoid

Cabozantinib: MRP2 Inhibitors may increase serum concentration of Cabozantinib. Risk C: Monitor

Chloramphenicol (Ophthalmic): May increase adverse/toxic effects of Myelosuppressive Agents. Risk C: Monitor

Chloramphenicol (Systemic): Myelosuppressive Agents may increase myelosuppressive effects of Chloramphenicol (Systemic). Risk X: Avoid

Cladribine: Agents that Undergo Intracellular Phosphorylation may decrease therapeutic effects of Cladribine. Risk X: Avoid

Clarithromycin: May increase myelosuppressive effects of Zidovudine. Clarithromycin may decrease serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction. Risk D: Consider Therapy Modification

CloZAPine: Myelosuppressive Agents may increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Deferiprone: Myelosuppressive Agents may increase neutropenic effects of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider Therapy Modification

Dexketoprofen: May increase adverse/toxic effects of Zidovudine. Risk C: Monitor

DOXOrubicin (Conventional): May decrease therapeutic effects of Zidovudine. DOXOrubicin (Conventional) may increase adverse/toxic effects of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine due to the possibility of reduced zidovudine efficacy and increased myelosuppressive effects. Risk D: Consider Therapy Modification

DOXOrubicin (Liposomal): May decrease therapeutic effects of Zidovudine. DOXOrubicin (Liposomal) may increase adverse/toxic effects of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine. Reduced efficacy of zidovudine is possible based on in vitro data. Also, increased myelosuppressive effects are possible with combined administration. Risk D: Consider Therapy Modification

Elivaldogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Elivaldogene Autotemcel. Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished Risk X: Avoid

Fedratinib: May increase serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Fedratinib: May increase serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Fexinidazole: Myelosuppressive Agents may increase myelosuppressive effects of Fexinidazole. Risk X: Avoid

Foslevodopa: May increase serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Ganciclovir-Valganciclovir: May increase adverse/toxic effects of Zidovudine. Specifically, hematologic toxicity may be enhanced. Risk C: Monitor

Gilteritinib: May increase serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Givinostat: May increase serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Risk C: Monitor

Interferons: May increase adverse/toxic effects of Zidovudine. Interferons may decrease metabolism of Zidovudine. Risk C: Monitor

Levomethadone: May increase serum concentration of Zidovudine. Risk C: Monitor

Linezolid: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Lopinavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Lovotibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Lovotibeglogene Autotemcel. Risk X: Avoid

Methadone: May increase serum concentration of Zidovudine. Risk C: Monitor

Nelfinavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Nirmatrelvir and Ritonavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Olaparib: Myelosuppressive Agents may increase myelosuppressive effects of Olaparib. Risk C: Monitor

Orlistat: May decrease serum concentration of Antiretroviral Agents. Risk C: Monitor

Probenecid: May increase serum concentration of Zidovudine. Risk C: Monitor

Promazine: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Raltegravir: May increase myopathic (rhabdomyolysis) effects of Zidovudine. Risk C: Monitor

Ribavirin (Oral Inhalation): Zidovudine may increase adverse/toxic effects of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors. Risk D: Consider Therapy Modification

Ribavirin (Systemic): Zidovudine may increase adverse/toxic effects of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors. Risk D: Consider Therapy Modification

RifAMPin: May decrease serum concentration of Zidovudine. Risk C: Monitor

Risdiplam: May increase serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate. Risk D: Consider Therapy Modification

Ritonavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Ropeginterferon Alfa-2b: Myelosuppressive Agents may increase myelosuppressive effects of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider Therapy Modification

Sorbitol: May decrease serum concentration of LamiVUDine. Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure. Risk D: Consider Therapy Modification

Stavudine: Zidovudine may decrease therapeutic effects of Stavudine. Risk X: Avoid

Tafenoquine: May increase serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling. Risk D: Consider Therapy Modification

Tafenoquine: May increase serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling. Risk D: Consider Therapy Modification

Tenoxicam: May increase adverse/toxic effects of Zidovudine. Risk C: Monitor

Tipranavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Trimethoprim: May increase serum concentration of LamiVUDine. Risk C: Monitor

Trimethoprim: Zidovudine may increase neutropenic effects of Trimethoprim. Trimethoprim may increase serum concentration of Zidovudine. Risk C: Monitor

Valproic Acid and Derivatives: May increase serum concentration of Zidovudine. Risk C: Monitor

Vimseltinib: May increase serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid concomitant use of vimseltinib and OCT2 substrates when possible. If combined, monitor for increased effects and toxicities of the OCT2 substrate and consider dose adjustments. Risk D: Consider Therapy Modification

Reproductive Considerations

Lamivudine in combination with zidovudine is an alternative regimen for patients with HIV infection who are not yet pregnant but are trying to conceive (HHS [perinatal] 2024).

Refer to individual monographs for additional information.

Pregnancy Considerations

Lamivudine in combination with zidovudine is an alternative NRTI backbone for pregnant patients with HIV infection who are antiretroviral-naive, who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking this combination may continue if viral suppression is effective and the regimen is well tolerated. Although use of this combination has significant experience for use in pregnancy, it has an increased potential for adverse events and requires twice-daily dosing (HHS [perinatal] 2024).

Refer to individual monographs for additional information.

Breastfeeding Considerations

Lamivudine and zidovudine are both present in breast milk.

Refer to individual monographs for additional information.

Monitoring Parameters

Amylase, bilirubin, signs and symptoms of pancreatitis. Monitor CBC with differential and platelet count at least every 2 weeks, liver function tests (including signs/symptoms of hepatomegaly), MCV, serum creatinine kinase, viral load, and CD4 count; observe for appearance of opportunistic infections; signs of muscle weakness or pain; blood lactate levels and signs of acidosis

Mechanism of Action

The combination of zidovudine and lamivudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance

Pharmacokinetics (Adult Data Unless Noted)

See individual agents.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Apo lamivudine zidovudine;
(AR) Argentina: 3 tc/azt elea | 3tc complex | Ganvirel duo | Hivirux complex | Imunoxa complex | Kess complex | Lamivudina + Zidovudina dosa | Muvidina | Ultraviral duo | Zetavudin;
(AT) Austria: Combivir;
(AU) Australia: Combivir | Lamivudine Zidovudine alphapharm;
(BD) Bangladesh: Diavix;
(BE) Belgium: Combivir;
(BF) Burkina Faso: Avocomb kid | Lamivudine + zidovudine;
(BG) Bulgaria: Combivir;
(BR) Brazil: Biovir | Far manguinhos lamivudina+zidovudina | Farmanguinhos lamivudina + zidovudina | Furp lamivudina + zidovudina | Lafepe zidovudina + lamivudina;
(CH) Switzerland: Combivir | Lamivudin Zidovudin Mepha;
(CI) Côte d'Ivoire: Bivek | Lamihope z | Lamivudine and zidovudine | Zidolam;
(CL) Chile: Bivir | Combivir | Lamivudina/zidovudina | Lantynon duo;
(CN) China: Combivir;
(CO) Colombia: Cipladuovir | Combivir | Convudina | Duoviral | Lamivudina + zidovudina | Lamizovir | Lavuzid | Virdual | Zovilam | Zovilam ped;
(CZ) Czech Republic: Combivir | Lamivudin/zidovudin mylan;
(DE) Germany: Combivir | Lamivudin/Zidovudin beta | Lamivudin/Zidovudin Heumann | Lamivudin/zidovudin hormosan | Lamivudin/zidovudin puren | Lamivudine and zidovudine | Lamivudine/zidovudine teva | Lamizido;
(DO) Dominican Republic: Combivir | Dunox | Zidofin;
(EC) Ecuador: Combivir | Duovir | Duoviral | Duvirox | Lamivudina + zidovudina | Lamivudina y zidovudina | Lamivudina/zidovudina | Zidolamchem | Zidomax | Zidovudina + lamivudina nifa;
(EE) Estonia: Combivir;
(EG) Egypt: Lamizidine;
(ES) Spain: Combivir | Lamivudina/zidovudina accord | Lamivudina/Zidovudina Aurobindo | Lamivudina/Zidovudina Mylan | Lamivudina/Zidovudina teva;
(ET) Ethiopia: Lamivudine & zidovudine;
(FI) Finland: Combivir;
(FR) France: Combivir | Lamivudine zidovudine Zentiva | Lamivudine/zidovudine arrow | Lamivudine/zidovudine cristers | Lamivudine/zidovudine mylan | Lamivudine/Zidovudine Sandoz | Lamivudine/zidovudine teva;
(GB) United Kingdom: Combivir | Lamivudine/zidovudine | Lamivudine/Zidovudine Sandoz;
(GH) Ghana: Bivek;
(GR) Greece: Combivir | Lamivudine/zidovudine teva;
(HK) Hong Kong: Combivir;
(HR) Croatia: Combivir;
(HU) Hungary: Combivir | Lamivudine/zidovudine teva | Lazid;
(ID) Indonesia: Duviral;
(IE) Ireland: Combivir;
(IL) Israel: Combivir;
(IN) India: Combivir | Cytocom | Duovir | Lamda-z | Lamuzid | Lazid | Virocomb | Zidolam | Zidovex l | Zovilam;
(IT) Italy: Combivir | Lamivudine/zidovudine mylan | Lamivudine/Zidovudine Sandoz | Lamivudine/zidovudine teva;
(JP) Japan: Combivir;
(KE) Kenya: Aspen lamzid | Avocomb | Avocomb kid | Combivir | Duovir | Lamivudine & zidovudine | Lamivudine and zidovudine | Lamivudine/zidovudine | Lamozid | Lazid | Lazidariv | Zidolam;
(KR) Korea, Republic of: Combivir;
(LB) Lebanon: Condine;
(LT) Lithuania: Combivir | Lamivudine / zidovudine teva;
(LU) Luxembourg: Combivir | Lamivudine/Zidovudine Sandoz;
(LV) Latvia: Combivir | Lamivudine/Zidovudine Sandoz;
(MX) Mexico: Altair pro | Cirilen | Combivir | Duzibindo | Envamonte | Isismer | Mivutev | Omidum | Pinoremna | Vicrate | Zilamtec;
(MY) Malaysia: Arrow lz | Combivir | Hovid lambivir | Lamizido | Zovilam;
(NG) Nigeria: Combivir | Lamivudine & zidovudine | Lamivudine and zidovudine | Lamivudine/zidovudine | Lamzidan | Lazid | Zidolam;
(NL) Netherlands: Combivir | Lamivudine/zidovudine mylan | Lamivudine/Zidovudine Sandoz | Lamivudine/zidovudine teva;
(NO) Norway: Combivir;
(NZ) New Zealand: Combivir;
(PE) Peru: Combivir | Ganvirel duo | Lamivudina + zidovudina | Lamivudina y zidovudina | Perdolat | Zidolam;
(PH) Philippines: Combivir | Lodiz;
(PL) Poland: Combivir | Lamiwudyna/zydowudyna mylan | Lazivir;
(PR) Puerto Rico: Combivir | Lamivudine and zidovudine | Lamivudine/zidovudine;
(PT) Portugal: Combivir | Lamivudina + zidovudina accord | Lamivudina + Zidovudina Aurobindo | Lamivudina + Zidovudina Farmoz | Lamivudina + Zidovudina Generis | Lamivudina + Zidovudina Mylan | Lamivudina + zidovudina sandoz;
(PY) Paraguay: Duovir | Lamivudina zidovudina | Lamivudina zidovudina nl pharma | Muvidina | Zetavudin | Zidovudir;
(QA) Qatar: Combivir;
(RO) Romania: Combivir | Lamivudina/Zidovudina Mylan | Lamivudine/zidovudine teva;
(RU) Russian Federation: Combivir | Dizaverox | Emlazid | Lami-zidox | Lazevun | Virocomb | Zidolam | Zidovudine lamivudine | Zidovudine+lamivudine | Zidovudine+lamivudine vial | Zilacomb | Zilam tl;
(SA) Saudi Arabia: Combivir;
(SE) Sweden: Combivir;
(SG) Singapore: Combivir;
(SI) Slovenia: Combivir;
(SK) Slovakia: Combivir;
(SL) Sierra Leone: Lamivudine/zidovudine;
(SR) Suriname: Combivir | Duovir | Lazid;
(TH) Thailand: Combid | Zilarvir | Zovilam;
(TN) Tunisia: Combivir | Lamivudine/zidovudine mylan;
(TR) Turkey: Combivir;
(TW) Taiwan: Combivir | Duovir | Lamivudine zidovudine sandoz | Zidolam | Zovilam;
(TZ) Tanzania, United Republic of: Lamivudine and zidovudine | Lamivudine and zidovudine macleods | Lamivudine/zidovudine | Lamivudine/zidovudine matrix | Lamivudine/zidovudine mylan;
(UA) Ukraine: Combivir | Combivudine | Lamihop 3 | Lamivudine/zidovudine | Lasivudine | Lazid | Zidolam;
(UG) Uganda: Avocomb | Duovir | Lamivudine + zidovudine | Lamivudine and zidovudine | Lamozid;
(UY) Uruguay: Combivir | Kess complex | Lamivudina / Zidovudina ion | Lamivudina Compuesta | Muvidina | Zetavudin;
(VE) Venezuela, Bolivarian Republic of: Combivir;
(VN) Viet Nam: Lamzidocom;
(ZA) South Africa: Aspen lamzid | Auro lamizido | Avocomb | Cipla duovir | Colamziv | Combivir | Combozil | Divuwin | Duovir | Macleods Lamivudine/Zidovudine | Sonke Zidovudine+Lamivudine | Zovilam;
(ZM) Zambia: Aspen lamzid | Avocomb | Bivir | Combivir | Duovir | Lamivudine + zidovudine | Lamivudine 150mg + zidovudine 300mg | Lamivudine/zidovudine | Varivar | Zidolam | Zidovex l;
(ZW) Zimbabwe: Avocomb | Combivir | Lamivudine + zidovudine | Lamivudine and zidovudine | Varivar | Zovilam

Combivir (lamivudine/zidovudine) [prescribing information]. Durham, NC: ViiV Healthcare; August 2023.
Combivir (lamivudine/zidovudine) [product monograph]. Montreal, Quebec, Canada: ViiV Healthcare ULC; May 2023.
Epivir (lamivudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; September 2020.
Fillekes Q, Kendall L, Kitaka S, et al. Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. Pediatr Infect Dis J. 2014;33(5):495-498. doi:10.1097/INF.0000000000000143 [PubMed 24736440]
Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," Infect Control Hosp Epidemiol, 2013, 34(9): 875-92. [PubMed 23917901]
McCrary AW, Nyandiko WM, Ellis AM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. AIDS. 2020;34(4):539-548. doi:10.1097/QAD.0000000000002445 [PubMed 31794518]
Ovesen JL, Sammons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines. Updated January 31, 2023. Accessed March 2, 2023.
US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new. Updated December 19, 2024. Accessed December 30, 2024.
Williams PL, Correia K, Karalius B, et al. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. AIDS. 2018;32(16):2337-2346. doi:10.1097/QAD.0000000000001988 [PubMed 30102660]

Topic 10221 Version 326.0

خرید پکیج

Zidovudine and lamivudine: Drug information